Novavax Inc (NVAX) · Oct 29, 2026 · Other events
$125M milestone — Phase 3 trial initiation; $125 million payment
Novavax earned a $125 million milestone after Sanofi began its Phase 3 flu-COVID combination vaccine trial, adding cash and validating the partnership pipeline.
Novavax is operating as a lean, partnership-led vaccine platform, with Sanofi handling much of Nuvaxovid’s commercial reach while Novavax monetizes its vaccine technology, Matrix-M adjuvant and development rights. Its June 30, 2026 filing already identified the flu-COVID program as a major remaining milestone opportunity and said Sanofi was expanding Nuvaxovid commercialization across additional markets.
The partnership moved from planning into a real late-stage program. Sanofi has now dosed the fifth patient in a European Phase 3 trial combining Nuvaxovid with Sanofi’s high-dose flu vaccine, which triggers a $125 million payment to Novavax. This is more meaningful than another development update: the program has crossed into the clinical stage that can support eventual regulatory filings and commercialization.
| Milestone | Earned now | Future opportunity |
|---|---|---|
| Phase 3 initiation payment (CLA) | $125M | |
| Manufacturing technology transfer (CLA) | $75M | |
| U.S. combination-vaccine launch (CLA) | $225M |
The cash is immediate, but the larger value remains conditional. The filing says Novavax is eligible for a further $75 million when manufacturing technology transfer is completed, expected in mid-2027, and another $225 million after a successful U.S. launch. Those amounts are not revenue today; they depend on manufacturing, trial, regulatory and commercial execution.
This was partly anticipated, not a surprise from nowhere. Sanofi had already signaled its intention to be an early mover in combination vaccines and was in discussions around Phase 3 timing, so the direction of travel was known. The new information is that the trial has actually started and the first major combination-product milestone has been earned. The event also adds to a partnership that Novavax says has generated more than $1 billion in revenue to date.
Bottom line: This materially advances Novavax’s partnership-led business model: it delivers $125 million now and converts Sanofi’s combination-vaccine ambition into a late-stage clinical asset. The bigger commercial payoff is still ahead and remains dependent on successful trial, regulatory and launch execution.
Phase 3 readout and U.S. regulatory filing
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!